Dr. Varaprasad regarded that costly multinational recombinant vaccines had negligible market penetration, and had not tapped into the entire potential with the vaccine. He recognized that he could leverage India's homegrown scientists, the lower expense of labor, process innovation, plus a low-margins organization technique to exploit this opportun